AVITA Medical, Inc. (RCEL) Stock Forecast
RCEL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $13.41 average of analyst targets
- Upside to target
- +2.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.29
- 52-week range
- $3.27 – $13.41
RCEL analyst ratings
3 analystsNumber of analysts at each rating.
RCEL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RCEL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.29 | −$0.36 | −$0.23 | −$0.71 | +58.9% | 4 |
| Current fiscal year (2026) | $0.42 | −$1.34 | $1.48 | −$2.45 | +117.0% | 4 |
| Next fiscal year (2027) | −$0.60 | −$1.07 | $0.10 | $0.42 | −244.6% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RCEL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $31.8M | $31.8M | $32.1M | +20.6% | 4 |
| Current fiscal year (2026) | $124.1M | $123.7M | $125.7M | +23.0% | 6 |
| Next fiscal year (2027) | $156.1M | $150.5M | $170.7M | +25.8% | 6 |
RCEL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RCEL revenue: reported and forecast
RCEL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.29 | −$0.29 | −$0.29 | −$0.29 | −17.2% | 4 up · 0 down |
| Current fiscal year (2026) | $0.08 | $0.25 | $0.25 | $0.25 | $0.18 | +133.6% | 4 up · 0 down |
| Next fiscal year (2027) | −$0.86 | −$0.61 | −$0.60 | −$0.60 | −$0.60 | −29.5% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RCEL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RCEL beat in 5 of 12.
What analysts expect from RCEL
3 analysts cover AVITA Medical; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.41, 2.9% above the latest close of $13.04. Analysts expect earnings of $0.42 per share for 2026, +117.0% from a year earlier. For 2027 the average estimate is −$0.60 per share on revenue of $156.1 million. AVITA Medical beat the EPS estimate in 5 of the last 12 quarters.
Related: RCEL income statement, RCEL key metrics, RCEL chart. See the RCEL stock overview for the latest quote and news.
RCEL forecast FAQ
What is AVITA Medical's price target?
The average analyst price target for AVITA Medical is $13.41, 2.9% above the latest close of $13.04.
Is AVITA Medical a buy, hold or sell?
Of 3 analysts covering AVITA Medical, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AVITA Medical's EPS forecast?
Analysts forecast $0.42 per share for 2026 (range −$1.34 to $1.48); for 2027 the estimate is −$0.60.
What is AVITA Medical's revenue forecast?
The average revenue estimate for 2026 is $124.1 million, growth of 23.0%; for 2027 it is $156.1 million.
When does AVITA Medical report earnings?
AVITA Medical is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.29.
Does AVITA Medical usually beat earnings estimates?
AVITA Medical reported EPS at or above the analyst estimate in 5 of the last 12 quarters.